{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:46Z","timestamp":1777870366611,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40620-020-00920-z","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T05:03:09Z","timestamp":1609563789000},"page":"1373-1380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Eculizumab interruption in atypical hemolytic uremic syndrome due to shortage: analysis of a Brazilian cohort"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7442-3354","authenticated-orcid":false,"given":"Miguel Ernandes","family":"Neto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"de Moraes Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halita Vieira Gallindo","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Si","family":"Nga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane Moyses","family":"Bravin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Cesar Andriotti","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Costa","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Brum","family":"Von Kriiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Martins","family":"Quinino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane Brand\u00e3o Bandeira","family":"de Mello Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Izabel","family":"de Holanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Helena","family":"Vaisbich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice Pignaton","family":"Naseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianna Mastroianni","family":"Kirsztajn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian Monteiro Pereira","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds Gustavo Modelli","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"issue":"3","key":"920_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"THJ Goodship","year":"2017","unstructured":"Goodship THJ, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi V, Kavanagh D et al (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 91(3):539\u2013551","journal-title":"Kidney Int"},{"issue":"23","key":"920_CR2","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 368(23):2169\u20132181","journal-title":"N Engl J Med."},{"issue":"5","key":"920_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ et al (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87(5):1061\u20131073","journal-title":"Kidney Int"},{"issue":"1","key":"920_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO et al (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68(1):84\u201393","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"920_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P et al (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89(3):701\u2013711","journal-title":"Kidney Int"},{"issue":"3","key":"920_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/ckj\/sfx024","volume":"10","author":"E Rodriguez","year":"2017","unstructured":"Rodriguez E, Barrios C, Soler MJ (2017) Shouldeculizumab be discontinued in patients with atypical hemolytic uremic syndrome? Clin Kidney J 10(3):320\u2013322","journal-title":"Clin Kidney J"},{"issue":"2","key":"920_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000492033","volume":"48","author":"SR Olson","year":"2018","unstructured":"Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG (2018) When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol 48(2):96\u2013107","journal-title":"Am J Nephrol"},{"issue":"3","key":"920_CR8","first-page":"310","volume":"10","author":"M Macia","year":"2017","unstructured":"Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C et al (2017) Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J 10(3):310\u2013319","journal-title":"Clin Kidney J"},{"issue":"4","key":"920_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S et al (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64(4):633\u2013637","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"920_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","volume":"66","author":"G Ardissino","year":"2015","unstructured":"Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V (2015) Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 66(1):172\u2013173","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"920_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Prov\u00f4t F, Delmas Y, Barbet C, Ch\u00e2telet V et al (2017) Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am SocNephrol. 12(1):50\u201359","journal-title":"Clin J Am SocNephrol."},{"key":"920_CR12","first-page":"22","volume":"54","author":"R Caetano","year":"2020","unstructured":"Caetano R, Rodrigues PHA, Corr\u00eaa MCV, Villardi P, Osorio-de-Castro CGS (2020) The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health. Rev Sa\u00fadeP\u00fablica 54:22","journal-title":"Rev Sa\u00fadeP\u00fablica"},{"issue":"6","key":"920_CR13","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","volume":"97","author":"V Brocklebank","year":"2020","unstructured":"Brocklebank V, Kumar G, Howie AJ, Chandar J, Milford DV, Craze J et al (2020) Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int 97(6):1260\u20131274","journal-title":"Kidney Int"},{"issue":"1","key":"920_CR14","first-page":"31","volume":"67","author":"CM Nester","year":"2015","unstructured":"Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship THJ et al (2015) Atypical aHUS: state of the art. MolImmunol 67(1):31\u201342","journal-title":"MolImmunol"},{"issue":"3","key":"920_CR15","first-page":"1","volume":"13","author":"LMP Palma","year":"2020","unstructured":"Palma LMP, Eick RG, Dantas GC, Tino MKS, de Holanda MI (2020) Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J 13(3):1\u201310","journal-title":"Clin Kidney J"},{"issue":"5","key":"920_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"On behalf of the ACMG Laboratory Quality Assurance Committee, Richards S, Aziz N, Bale S, Bick D, Das S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013423","journal-title":"Genet Med"},{"issue":"10","key":"920_CR17","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am SocNephrol 5(10):1844\u20131859","journal-title":"Clin J Am SocNephrol"},{"issue":"3","key":"920_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.kint.2019.05.008","volume":"96","author":"CA Cassol","year":"2019","unstructured":"Cassol CA, Brodsky SV, Satoskar AA, Blissett AR, Cataland S, Nadasdy T (2019) Eculizumab deposits in vessel walls in thrombotic microangiopathy. Kidney Int 96(3):761\u2013768","journal-title":"Kidney Int"},{"issue":"5","key":"920_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5500\/wjt.v8.i5.122","volume":"8","author":"F Abbas","year":"2018","unstructured":"Abbas F, Kossi ME, Kim JJ, Sharma A, Halawa A (2018) Thrombotic microangiopathy after renal transplantation: current insights in de novo and recurrent disease. World J Transplant 8(5):122\u2013141","journal-title":"World J Transplant"},{"issue":"11","key":"920_CR20","first-page":"2261","volume":"34","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ (2019) Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. PediatrNephrol 34(11):2261\u20132277","journal-title":"PediatrNephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00920-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-020-00920-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00920-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:05Z","timestamp":1777564505000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/4\/1373\/8325811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["920"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00920-z","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"5 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.I.H., M.H.V., L.M.P.P. and L.G.M.A. have received fees for participation in teaching courses from Alexion Pharmaceuticals as speakers. M.E.N., L.M.S., H.V.G.V, H.S.N., A.M.B., J.C.A.B., R.C.G., R.B.V.K., R.M.Q., V.B.B.M.S., A.P.N. and G.M.K. have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Ethics Committee of Universidade Estadual Paulista (UNESP), S\u00e3o Paulo State University (ethics number: 2.772.340). The study was performed according to the Declaration of Helsinki. All participants provided written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}